Histone deacetylase inhibitors: An analysis of recent patenting activity

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 7, 2007, Pages 745-765

  Price, Steve ^a   Dyke, Hazel J ^a  

^a Argenta Discovery Ltd   (United Kingdom)

Author keywords

Benzamide; Cyclic peptide; Depsipeptide; FK228; Histone deacetylase inhibitor; Hydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat

Indexed keywords

1,2,3,4 TETRAHYDROISOQUINOLINE HYDROXAMIC ACID DERIVATIVE; 2 AMINOBENZAMIDE; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; AMIDOHYDROLASE INHIBITOR; AMINOMETHYLPROPENYLBENZOHYDROXYAMIDE DERIVATIVE; ARYLBUTYRIC ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOTHIOPHENE 2 CARBOXYLIC ACID HYDROXYAMIDE DERIVATIVE; BUTYRIC ACID; CINNAMYL HYDROXAMIC ACID DERIVATIVE; CRA 024781; CRA 026440; FR 901228; GENERIC DRUG; HETEROAROMATIC HYDROXAMIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; MERCAPTOKETONE DERIVATIVE; MGCD 0103; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NVP LBH 589; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; SILANEDIOL DERIVATIVE; SNDX 275; THIOL DERIVATIVE; THIOPHENE 2 CARBOXYLIC ACID HYDROXYAMIDE DERIVATIVE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG INDUSTRY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; IC 50; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATENT; REVIEW; SPINAL MUSCULAR ATROPHY;

EID: 34547858930     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.7.745     Document Type: Review

References (35)

1. YOO CB, JONES PA: Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. (2006) 5:37-50.
2. INCHE AG, LA THANGUE NB: Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov. Today (2006) 11:97-108.
3. LIN H-Y, CHEN C-S, LIN S-P: Targeting histone deacetylase in cancer therapy. Med Res. Rev. (2006) 26:397-413.
4. JOHNSTONE RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. (2002) 1:287-299.
5. BOLDEN JE, PEART MJ, JOHNSTONE RW: Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. (2006) 5:769-784.
6. KRISTELEIT R, STIMSON L, WORKMAN P et al.: Histone modification enzymes: novel targets for cancer drugs. Expert Opin. Emerg. Drugs (2004) 9:135-154.
7. CAREY N, LA THANGUE NB: Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol. (2006) 6:369-375.
8. MAI A, SILVIO M, ROTILI D et al.: Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J. Med. Chem. (2006) 49:6046-6056.
9. WEINMANN E, OTTOW E: Histone deacetylase inhibitors: a survey of recent patents. Expert Opin. Ther. Patents (2005) 15:1677-1690.
10. MILLER TA: Patent status of histone deacetylase inhibitors. Expert Opin. Ther. Patents (2004) 14:791-804.
11. CURTIN ML: Current patent status of histone deacetylase inhibitors. Expert Opin. Ther. Patents (2002) 12:1375-1384.
12. ROSATO RR, GRANT S: Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs (2004) 13:21-38.
13. MARKS PA, DOKMANOVIC M: Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs (2005) 14:1497-1511.
14. KELLY WK, O'CONNOR CA, KRUG LM et al.: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. (2005) 23:3923-3931.
15. O'CONNOR OA, HEANEY MI, SCHWARTZ L: Clinical experience with intravenous and oral formulations of the novel histone deacerylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. (2006) 24:116-173.
16. KELLY WK, RICHON VM, O'CONNOR O: Phase I clinical trial of histone deacetylase inhibitor. suberoylanilide hydroxamic acid administered intraveneously. Clin. Cancer Res. (2003) 9:3578-3588.
17. KELLAND L: Discontinued drugs in 2005: oncology drugs. Expert Opin. Investig. Drugs (2006) 15:1309-1318.
18. PRICE S, BORDOGNA W. BRAGANZA R et al.: Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett. (2007) 15:363-369.
19. PRICE S, BORDOGNA W, BULL RJ et al.: Identification and oprimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacerylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett. (2007) 15:370-375.
20. SUZUKI T, KOUKETSU A, MATSUURA A et al.: Thiol-based SARA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:3313-3317.
21. SUZUKI T, NAGANO Y, KOUKETSU A et al.: Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J. Med. Chem. (2005) 48(4):1019-1032.
22. SUZUKI T, MATSUURA A, KOUKETSU A et al.: Identification of a potent non-hydroxamate histone deactylase inhibitor by mechanism-based drug design. Bioorg. Med. Chem. Lett. (2005) 15:331-335.
23. CHEN B, PETUKHOV PA, JUNG M et al.: Chemistry and biology of mercaptoamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:1389-1392.
24. AANADAN S-K, WARD JS, BROKX RD et al.: Mercaptoamide-based non-hydroxamic acid type histone deacerylase inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:1969-1972.
25. SIEBURTH SM, CHEN C-A: Silanediol protease inhibitors: from conception to validation. Eur. J. Org. Chem. (2006) 2:311-322.
26. FARACO G, TRISTANO P, FORMENTINI L et al.: Pharmacological inhibition of histone deactylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Phamacol. (2006) 70(6):1876-1884.
27. DE BOER J, LICHT R, BONGERS M et al.: Inhibition of histone acetylation as a tool in bone tissue engineering. Tissue Eng. (2006) 12(10):2927-2937.
28. LEE HW, SUH JH, KIM AY et al.: Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol. Endocrinol. (2006) 20(10):2432-2443.
29. OKAMOTO H, TAKAHASHI A, TAKAHASHI T et al.: Trichostarin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21WAF1. J. Atheroscler. Thromb. (2006) 13(4):183-191.
30. LENG C, GRIES M, ZIEGLER J et al.: Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp. Hematol. (2006) 34(6):776-787.
31. STEFFAN JS, BODAL L, PALLOS J et al.: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature (2001) 413(6857):739-743.
32. HOCKLY E, RICHON VM, WOODMAN B et al.: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Hunrington's disease. PNAS (2003) 100(4):2041-2046.
33. SADRI-VAKILI G, CHA J-HJ: Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr. Alzheimer Res. (2006) 3(4):403-408.
34. HAHNEN E, EYUEPOGLU IY, BRICHTA L et al.: In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. (2006) 98(1): 193-202.
35. SIMONINI MY, CAMARGO LM, DONG E et al.: The benzamide SNDX-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. PNAS (2006) 103(5):1587-1592.